NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $9.47 -0.53 (-5.30%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.77▼$9.9050-Day Range$6.81▼$12.2752-Week Range$4.96▼$49.00Volume180,265 shsAverage Volume104,770 shsMarket Capitalization$45.62 millionP/E RatioN/ADividend YieldN/APrice Target$185.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Atara Biotherapeutics alerts: Email Address Atara Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside1,858.8% Upside$185.50 Price TargetShort InterestBearish9.37% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.12Based on 5 Articles This WeekInsider TradingSelling Shares$39,309 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($12.09) to ($16.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector268th out of 910 stocksBiological Products, Except Diagnostic Industry37th out of 155 stocks 3.1 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.37% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Atara Biotherapeutics has recently increased by 4.99%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 2.3 News and Social Media Coverage News SentimentAtara Biotherapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows1 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,309.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Atara Biotherapeutics is held by insiders.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($12.09) to ($16.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Atara Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Atara Biotherapeutics Stock (NASDAQ:ATRA)Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Read More ATRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRA Stock News HeadlinesAugust 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $12,073.23 in StockSeptember 7 at 2:01 AM | americanbankingnews.comAnalysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $185.50September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 4 at 6:29 PM | finance.yahoo.comAtara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4 at 6:29 PM | msn.comAtara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?September 3, 2024 | marketwatch.comAtara Biotherapeutics Shares Climb on $36 Million Direct OfferingSeptember 3, 2024 | finance.yahoo.comAtara Biotherapeutics Announces $36 Million Registered Direct OfferingAugust 19, 2024 | markets.businessinsider.comAtara Biotherapeutics (ATRA) Gets a Hold from Stifel NicolausSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 17, 2024 | msn.comMizuho Upgrades Atara Biotherapeutics (ATRA)August 15, 2024 | uk.finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 14, 2024 | finance.yahoo.comAtara Biotherapeutics Second Quarter 2024 Earnings: Misses ExpectationsAugust 12, 2024 | msn.comATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | msn.comTSX inches up; investors cautious ahead of US dataAugust 12, 2024 | ca.finance.yahoo.comStock market today: Nasdaq edges higher, Dow drops as investors await key signals on inflation, economyAugust 12, 2024 | nz.finance.yahoo.comNickelodeon Marketing Exec Sabrina Caluori Exiting Ahead Of Broader Paramount LayoffsAugust 12, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership UpdateAugust 7, 2024 | finance.yahoo.comAtara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceSee More Headlines Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$185.50 High Stock Price Target$700.00 Low Stock Price Target$11.00 Potential Upside/Downside+1,858.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($53.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,130,000.00 Net Margins-290.20% Pretax Margin-290.18% Return on EquityN/A Return on Assets-113.71% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.29 Sales & Book Value Annual Sales$62.39 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value($22.56) per share Price / Book-0.42Miscellaneous Outstanding Shares4,817,000Free Float4,639,000Market Cap$45.62 million OptionableOptionable Beta0.52 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Pascal Touchon D.V.M. (Age 61)President, CEO & Director Comp: $1.08MMr. K. Amar Murugan (Age 48)Executive VP & Chief Legal Officer Comp: $618.52kMr. Eric Hyllengren (Age 48)Executive VP & Chief Financial Officer Dr. Anhco Nguyen Ph.D. (Age 51)Executive VP and Chief Scientific & Technical Officer Alex ChapmanVice President of Corporate Communications & Investor RelationsMs. Jill Henrich (Age 61)Executive VP and Global Head of Regulatory Affairs & Quality Mr. Dan MaziaszExecutive VP & Chief Business OfficerMs. Rajani Dinavahi M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXAlloVirNASDAQ:ALVRCardiol TherapeuticsNASDAQ:CRDLKodiak SciencesNASDAQ:KODCadrenal TherapeuticsNASDAQ:CVKDView All CompetitorsInsiders & InstitutionsPascal TouchonSold 3,038 sharesTotal: $20,141.94 ($6.63/share)Anhco NguyenSold 1,821 sharesTotal: $12,073.23 ($6.63/share)Eric J HyllengrenSold 1,070 sharesTotal: $7,094.10 ($6.63/share)AQR Capital Management LLCSold 2,610,389 shares on 8/15/2024Ownership: 0.313%Point72 Asia Singapore Pte. Ltd.Bought 6,292 shares on 8/15/2024Ownership: 0.131%View All Insider TransactionsView All Institutional Transactions ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $12.82 at the start of the year. Since then, ATRA shares have decreased by 26.1% and is now trading at $9.47. View the best growth stocks for 2024 here. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings data on Monday, August, 12th. The biotechnology company reported ($3.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by $1.54. The biotechnology company had revenue of $28.64 million for the quarter, compared to analyst estimates of $48.30 million. When did Atara Biotherapeutics' stock split? Atara Biotherapeutics shares reverse split before market open on Thursday, June 20th 2024. The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. Who are Atara Biotherapeutics' major shareholders? Atara Biotherapeutics' top institutional investors include Acadian Asset Management LLC (2.48%), Renaissance Technologies LLC (0.96%), AQR Capital Management LLC (0.31%) and Cubist Systematic Strategies LLC (0.19%). Insiders that own company stock include Pascal Touchon, Anhco Nguyen, Eric J Hyllengren, Carol Giltner Gallagher, Jakob Dupont, Amar Murugan, William K Heiden, Utpal Koppikar, Matthew K Fust and Joe Newell. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and OPKO Health (OPK). This page (NASDAQ:ATRA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
